Robert Duggan (Kelly Morfopoulos via Wikimedia)
October 5, 2020 07:21 AM EDTUpdated 07:52 AM
R&D

With Covid-19 muck­ing the tires, Robert Dug­gan throws an­oth­er $50M be­hind his big an­tibi­otics play

Jason Mast

Editor

Robert Dug­gan is up­ping his ante on Sum­mit Ther­a­peu­tics.

The bil­lion­aire in­vestor qui­et­ly bid up to 65% of the small an­tibi­ot­ic de­vel­op­er be­fore

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times